Abstract 13212: Chronic Total Occlusion Racial and Income Inequities by Mortality and Cost: Propensity Score and Machine Learning Augmented Nationally Representative Case-Control Study of 30 Million Hospitalizations

Abstract

Introduction: We sought to produce the first nationally representative analysis of racial and income inequities by mortality and cost for patients with chronic total occlusion (CTO) of coronary arteries by the presence or absence of active cancer. Methods: Propensity score adjusted and backward propagation neural network machine learning augmented multivariable regression among patients with CTO and stratified by race and income was conducted for the above outcomes in this case-control study of the United States’ largest and most current all-payer hospitalized dataset, the 2016 National Inpatient Sample. Regression models were fully adjusted for age, geographic region, anemia, thrombocytopenia, cancer metastases, NIS-calculated mortality risk by Diagnosis Related Group (DRG), and the likelihood of undergoing PCI (in addition to length of stay [LOS] for cost). To produce nationally representative estimates, analyses were also adjusted for the complex survey design. Results: Of the 30,195,722 adult hospitalized patients, 1,159,994 (3.84%) underwent PCI (of whom 30,624 [2.64%] were in patients with active cancer), and 120,815 (0.40%) had CTO (of whom 3,068 [2.54%] had active cancer). In multivariable regression among patients with CTO, mortality was comparable across races in both PCI and cancer, but significantly increased among the lowest income quartile for patients with cancer (OR 4.09; 95%CI 1.30-12.80; p=0.016). PCI in Hispanic cancer patients unlike other races had significantly increased costs ($207,218.80; 95%CI 76,799.21-337,738.30; p=0.002) as did the lowest income quartile ($26,327.08; 95%CI 21,123.93-31,530.23; p=0.042) unlike other income groups significantly increased costs. Conclusions: This large nationally representative study suggests PCI can safely done in hospitalized patients with CTO and active cancer though its prevalence is far less than in those without cancer despite comparable risk profiles; there also appears to be significant racial and income inequities in both mortality and cost by both race and income.